Progression of Follicular Thyroid Carcinomas to Anaplastic Thyroid Carcinomas: Molecular and Clinicopathologic Characteristics with Comparison to Papillary Thyroid Carcinoma-Derived Anaplastic Thyroid Carcinomas
- PMID: 40887557
- DOI: 10.1007/s12022-025-09875-y
Progression of Follicular Thyroid Carcinomas to Anaplastic Thyroid Carcinomas: Molecular and Clinicopathologic Characteristics with Comparison to Papillary Thyroid Carcinoma-Derived Anaplastic Thyroid Carcinomas
Abstract
Although anaplastic thyroid carcinomas (ATCs) typically arise from papillary thyroid carcinomas (PTCs), follicular thyroid carcinomas (FTCs) can also progress to ATCs; however, histologically confirmed FTC-derived ATCs are relatively uncommon and remain poorly characterized. To clarify this phenomenon, we analyzed eight FTC-derived ATCs and compared them with 11 PTC-derived ATCs. Whole-exome sequencing (WES) was conducted on the differentiated thyroid carcinoma (DTC) and ATC components within the same tumors to examine mutational profiles; three additional cases underwent FoundationOne® testing. The demographic features were similar between FTC- and PTC-derived ATCs. Histologically, spindle-cell morphology was more common in FTC-derived ATCs (3/8), whereas PTC-derived ATCs exhibited squamoid (5/11) and giant cell features (5/11), including osteoclast-like cells. WES was successfully performed on both the ATC and FTC components in seven of the eight FTC-derived ATCs. Common alterations included TERT promoter (5/7), NRAS (4/7), and HRAS (2/7) mutations in both components. TP53 mutations were observed only in the ATC component (5/7). EIF1AX mutations co-occurred with TERT and HRAS mutations in two cases. PTEN mutations were found in two FTCs with solid/trabecular patterns but were absent in the corresponding ATC components. One tumor harbored a DGCR8 p.E518K mutation that was retained during progression. By contrast, PTC-derived ATCs consistently showed concurrent BRAF and TERT promoter mutations (11/11). Immunohistochemistry for BRAF V600E, RAS Q61R, p53, PTEN, and MTAP showed high concordance with the corresponding mutation status. These findings revealed significant histological and genetic differences between FTC- and PTC-derived ATCs, providing new insights into the molecular basis of FTC dedifferentiation into ATC.
Keywords: Anaplastic thyroid carcinoma; Follicular thyroid carcinoma; Mutation; Papillary thyroid carcinoma; Progression.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics Approval: The Institutional Review Boards of the National Cancer Center Hospital (2010–077) and Ito Hospital (471) approved this study. Consent to Participate: Not applicable. Consent for Publication: All authors agree to the publication of this manuscript. Competing interests: The authors have no conflict of interest to declare.
Similar articles
-
High Prevalence of TBC1D12 5'UTR Mutations in Anaplastic Thyroid Cancer.Thyroid. 2025 Jan;35(1):115-119. doi: 10.1089/thy.2024.0345. Epub 2024 Dec 16. Thyroid. 2025. PMID: 39682039
-
Involvement of KEAP1/NRF2 pathway in non-BRAF mutated squamous cell carcinoma of the thyroid.J Pathol. 2025 Aug;266(4-5):481-494. doi: 10.1002/path.6444. Epub 2025 Jul 2. J Pathol. 2025. PMID: 40600748 Free PMC article.
-
Association Between Gross Features and Coexistence of BRAFV600E and TERT Promoter Mutations in Papillary Thyroid Carcinomas: A Combined Analysis Incorporating Clinicopathologic Features.Thyroid. 2024 Dec;34(12):1476-1485. doi: 10.1089/thy.2024.0310. Epub 2024 Oct 31. Thyroid. 2024. PMID: 39479802
-
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073. Cancer. 2005. PMID: 15880523 Review.
-
Epigenetic silencing of the tumor suppressor TIMP-3 gene in upstream CpG islands in thyroid neoplasms: a cross-sectional study with systematic review.Mol Biol Rep. 2025 Jul 1;52(1):665. doi: 10.1007/s11033-025-10721-x. Mol Biol Rep. 2025. PMID: 40593331
References
-
- Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O (2022) Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol 33 (1):27-63. https://doi.org/10.1007/s12022-022-09707-3 - DOI - PubMed
-
- Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126 (3):1052-1066. https://doi.org/10.1172/jci85271 - DOI - PubMed - PMC
-
- Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW (2018) Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res 24 (13):3059-3068. https://doi.org/10.1158/1078-0432.Ccr-18-0373 - DOI - PubMed - PMC
-
- Zhang L, Ren Z, Su Z, Liu Y, Yang T, Cao M, Jiang Y, Tang Y, Chen H, Zhang W, Gong R, Wei T, Peng Y, Liu B, Zhang W, Yang L, Hu Y, Li Z, Zhu J, Xu H, Shu Y, Luo H (2021) Novel Recurrent Altered Genes in Chinese Patients With Anaplastic Thyroid Cancer. J Clin Endocrinol Metab 106 (4):988-998. https://doi.org/10.1210/clinem/dgab014 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous